Home » Stocks » YMAB

Y-mAbs Therapeutics, Inc. (YMAB)

Stock Price: $32.75 USD 1.45 (4.63%)
Updated May 13, 2021 4:00 PM EDT - Market closed
Market Cap 1.43B
Revenue (ttm) 26.13M
Net Income (ttm) -59.75M
Shares Out 43.57M
EPS (ttm) -1.47
PE Ratio n/a
Forward PE 112.36
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $32.75
Previous Close $31.30
Change ($) 1.45
Change (%) 4.63%
Day's Open 31.85
Day's Range 31.22 - 33.69
Day's Volume 239,906
52-Week Range 24.77 - 55.22

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializat...

15 hours ago - GlobeNewsWire

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 22.95% and -91.91%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializat...

1 week ago - GlobeNewsWire

NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the first quarter ended Ma...

2 weeks ago - GlobeNewsWire

NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commerciali...

2 weeks ago - GlobeNewsWire

Y-mAbs Therapeutics Inc (NASDAQ: YMAB) recently concluded a Type B meeting with the FDA regarding omburtamab in CNS/leptomeningeal metastasis from neuroblastoma.  The company received requests from the ...

3 weeks ago - Benzinga

NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commerciali...

1 month ago - GlobeNewsWire

NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a development-stage clinical biopharmaceutical company focused on the development and com...

2 months ago - GlobeNewsWire

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercializ...

2 months ago - GlobeNewsWire

NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the fiscal year ended Decem...

2 months ago - GlobeNewsWire

Y-mAbs Therapeutics Inc (NASDAQ: YMAB) priced its public offering of 2.4 million common shares at $41 per share, for gross proceeds of approximately $100 million. Underwriters have an option to purchase...

2 months ago - Benzinga

NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercializ...

2 months ago - GlobeNewsWire

NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial stage biopharmaceutical company focused on the development and commercializ...

2 months ago - GlobeNewsWire

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializa...

4 months ago - GlobeNewsWire

NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializa...

4 months ago - GlobeNewsWire

Y-mAbs Therapeutics recently had its first approval. Its second drug, despite some hiccups, is on its way to the market.

4 months ago - Seeking Alpha

Overland Pharmaceuticals will form a $117 million China JV with Allogene Therapeutics to bring allogenic CAR-T drugs to China. Harbour BioMed has out-licensed its fully human SARS-CoV-2 neutralizing ant...

Other stocks mentioned: ABBV, ADCT, ALLO, BNTX, LEGN
4 months ago - Seeking Alpha

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializa...

4 months ago - GlobeNewsWire

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializa...

4 months ago - GlobeNewsWire

NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializa...

4 months ago - GlobeNewsWire

NEW YORK and PETACH TIKVA, Israel, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) (the “Company” or “Y-mAbs”) a commercial-stage biopharmaceutical company focused on the deve...

5 months ago - GlobeNewsWire

NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercializa...

5 months ago - GlobeNewsWire

NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercial...

5 months ago - GlobeNewsWire

Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

NEW YORK, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercial...

6 months ago - GlobeNewsWire

NEW YORK, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercial...

6 months ago - GlobeNewsWire

NEW YORK, Oct. 8, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB). Such investors are advised to...

7 months ago - PRNewsWire

NEW YORK, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercial...

7 months ago - GlobeNewsWire

NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercia...

7 months ago - GlobeNewsWire

Y-mAbs Is One To Accumulate Before PDUFA

8 months ago - Seeking Alpha

Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commerci...

9 months ago - GlobeNewsWire

NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commerc...

9 months ago - GlobeNewsWire

NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the second quarter ended ...

9 months ago - GlobeNewsWire

NEW YORK, July 27, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commerci...

9 months ago - GlobeNewsWire

NEW YORK, July 14, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commerci...

9 months ago - GlobeNewsWire

NEW YORK, June 30, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commerci...

10 months ago - GlobeNewsWire

While everyone's focused on COVID-19, these drugmakers are looking forward to unrelated FDA approvals that could push their stock prices into the clouds.

Other stocks mentioned: ACAD
10 months ago - The Motley Fool

This cancer-fighting biotech could have two approved drugs in the next year, and a whole lot more.

11 months ago - The Motley Fool

Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

NEW YORK, April 24, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc., (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commer...

1 year ago - GlobeNewsWire

NEW YORK, April 15, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commerc...

1 year ago - GlobeNewsWire

Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commerci...

1 year ago - GlobeNewsWire

NEW YORK, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commerc...

1 year ago - GlobeNewsWire

NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commerc...

1 year ago - GlobeNewsWire

NEW YORK, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commerc...

1 year ago - GlobeNewsWire

NEW YORK, Nov. 15, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commerc...

1 year ago - GlobeNewsWire

Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

NEW YORK, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commerci...

1 year ago - GlobeNewsWire

About YMAB

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neurob... [Read more...]

Industry
Biotechnology
IPO Date
Sep 21, 2018
Stock Exchange
NASDAQ
Ticker Symbol
YMAB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for YMAB stock is "Buy." The 12-month stock price forecast is 57.88, which is an increase of 76.73% from the latest price.

Price Target
$57.88
(76.73% upside)
Analyst Consensus: Buy